Based on the provided sources, there is limited information available regarding the specific risks of lurbinectedin to fetuses. The sources do not directly mention any specific risks or data related to fetal development or pregnancy. However, it is important to note that the available information may not be exhaustive, and further research or consultation with healthcare professionals is recommended for a comprehensive understanding of the topic.

The Drug Patent Watch website [1] provides information on the patent status and expiration dates of pharmaceutical drugs, including lurbinectedin. While it provides valuable information about the drug, it does not offer specific details about the risks to fetuses.

The FDA drug label for lurbinectedin [2] is an official document that provides important information about the drug, including its approved uses, dosage, and potential side effects. However, the label does not contain specific data or warnings related to the use of lurbinectedin during pregnancy or its potential risks to fetuses.

The Health Sciences Authority (HSA) of Singapore [3] provides a summary report on lurbinectedin, but it does not mention any information regarding the drug's effects on fetuses or pregnancy.

It is important to note that the absence of specific information on fetal risks does not necessarily indicate the absence of any risk. Lurbinectedin is a relatively new drug, and the available information may not cover all potential risks. Pregnant individuals or those planning to become pregnant should consult their healthcare provider before using lurbinectedin or any other medication to assess potential risks and benefits.

In conclusion, based on the provided sources, there is limited information available regarding the specific risks of lurbinectedin to fetuses. Further research or consultation with healthcare professionals is recommended for a comprehensive understanding of the topic.

Sources:
[1] Drug Patent Watch. Lurbinectedin. Retrieved from https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] U.S. Food and Drug Administration. Lurbinectedin FDA Label. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] Health Sciences Authority. Summary Report: Lurbinectedin. Retrieved from https://www.hsa.gov.sg/docs/default-source/hprg-tpb/summary-reports/vial-summary-report.pdf